Mathijs P. Hendriks
University of Twente
79 Papers
63 Citations
Mathijs P. Hendriks is an academic researcher from University of Twente. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 46 publications. Previous affiliations of Mathijs P. Hendriks include Radboud University Nijmegen Medical Centre & Radboud University Nijmegen.
Chat about Author
Papers
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Renu R. Bahadoer,Esmée A Dijkstra,Boudewijn van Etten,Corrie A.M. Marijnen,Corrie A.M. Marijnen,Hein Putter,Elma Meershoek-Klein Kranenbarg,Annet G H Roodvoets,Iris D. Nagtegaal,Regina G. H. Beets-Tan,Lennart Blomqvist,Tone Fokstuen,Albert J. ten Tije,Jaume Capdevila,Mathijs P. Hendriks,Ibrahim Edhemovic,Andrés Cervantes,Per Nilsson,Bengt Glimelius,Cornelis J.H. van de Velde,Geke A. P. Hospers,L. Østergaard,F. Svendsen Jensen,P. Pfeiffer,K.E.J. Jensen,M.P. Hendriks,W.H. Schreurs,H.P. Knol,J.J. van der Vliet,J.B. Tuynman,A.M.E. Bruynzeel,E.D. Kerver,S. Festen,M E van Leerdam,G.L. Beets,L.G.H. Dewit,C.J.A. Punt,Pieter J. Tanis,E.D. Geijsen,P. Nieboer,W.A. Bleeker,A.J. Ten Tije,R.M.P.H. Crolla,A.C.M. van de Luijtgaarden,J.W.T. Dekker,J.M. Immink,F.J.F. Jeurissen,A.W.K.S. Marinelli,H.M. Ceha,T.C. Stam,P. Quarles an Ufford,W.H. Steup,A.L.T. Imholz,R.J.I. Bosker,J.H.M. Bekker,G.J. Creemers,G.A.P. Nieuwenhuijzen,H. van den Berg,W.M. van der Deure,R.F. Schmitz,J.M. van Rooijen,A.F.T. Olieman,A.C.M. van den Bergh,Derk Jan A. de Groot,Klaas Havenga,Jannet C. Beukema,J. de Boer,P.H.J.M. Veldman,E.J.M. Siemerink,J.W.P. Vanstiphout,B. de Valk,Q.A.J. Eijsbouts,M.B. Polée,C. Hoff,A. Slot,H.W. Kapiteijn,K.C.M.J. Peeters,F.P. Peters,P.A. Nijenhuis,S.A. Radema,H. de Wilt,P. Braam,G.J. Veldhuis,D. Hess,T. Rozema,O. Reerink,D. Ten Bokkel Huinink,A. Pronk,Janet R. Vos,M. Tascilar,G.A. Patijn,C. Kersten,O. Mjåland,M. Grønlie Guren,A.N. Nesbakken,J. Benedik,I. Edhemovic,V. Velenik,J. Capdevila,E. Espin,R. Salazar,S. Biondo,V. Pachón,J. die Trill,J. Aparicio,E. Garcia Granero,M.J. Safont,J.C. Bernal,A. Cervantes,A. Espí Macías,L. Malmberg,G. Svaninger,H. Hörberg,G. Dafnis,A. Berglund,L. Österlund,K. Kovacs,J. Hol,S. Ottosson,G. Carlsson,C. Bratthäll,J. Assarsson,B.L. Lödén,P. Hede,I. Verbiené,O. Hallböök,A. Johnsson,M.L. Lydrup,K. Villmann,P. Matthiessen,J.H. Svensson,J. Haux,S. Skullman,T. Fokstuen,Torbjörn Holm,P. Flygare,M. Walldén,B. Lindh,O. Lundberg,C. Radu,L. Påhlman,A. Piwowar,K. Smedh,U. Palenius,S. Jangmalm,P. Parinkh,H. Kim,M.L. Silviera +147 more
TL;DR: The Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation (RAPIDO) trial aimed to reduce distant metastases without compromising locoregional control.
Explainable machine learning can outperform Cox regression predictions and provide insights in breast cancer survival.
Arturo Moncada-Torres,Marissa C. van Maaren,Mathijs P. Hendriks,Sabine Siesling,Gijs Geleijnse +4 more
TL;DR: It is shown that explainable ML can generate explicit knowledge of how models make their predictions, which is crucial in increasing the trust and adoption of innovative ML techniques in oncology and healthcare overall.
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial
Maxime J M van der Valk,Corrie A.M. Marijnen,Corrie A.M. Marijnen,Boudewijn van Etten,Esmée A Dijkstra,Denise E. Hilling,Elma Meershoek-Klein Kranenbarg,Hein Putter,Annet G H Roodvoets,Renu R. Bahadoer,Tone Fokstuen,Albert J. ten Tije,Jaume Capdevila,Mathijs P. Hendriks,Ibrahim Edhemovic,Andrés Cervantes,Derk Jan A. de Groot,Per Nilsson,Bengt Glimelius,Cornelis J.H. van de Velde,Geke A. P. Hospers +20 more
TL;DR: Although considerable toxicity was observed during preoperative therapy, this did not lead to differences in surgical procedures or postoperative complications, and high compliance of preoperative systemic treatment could be achieved with the experimental approach.
185
Locoregional Failure During and After Short-course Radiotherapy followed by Chemotherapy and Surgery Compared to Long-course Chemoradiotherapy and Surgery - A Five-year Follow-up of the RAPIDO Trial.
Esmée A Dijkstra,Per Nilsson,Geke A. P. Hospers,Renu R. Bahadoer,Elma Meershoek-Klein Kranenbarg,Annet G H Roodvoets,Hein Putter,Åke Berglund,Andrés Cervantes,Rogier M P H Crolla,Mathijs P. Hendriks,Jaume Capdevila,Ibrahim Edhemovic,Corrie A.M. Marijnen,Cornelis J.H. van de Velde,Bengt Glimelius,Boudewijn van Etten +16 more
TL;DR: In this paper , the authors analyzed risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at five years and found that the EXP treatment was associated with an increased risk of LRR whereas the reduction in disease-related treatment failure and distant metastases remained after 5 years.
67
Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features
Pauline A. J. Mendelaar,Marcel Smid,Job van Riet,Lindsay Angus,Mariette Labots,Neeltje Steeghs,Mathijs P. Hendriks,Geert A. Cirkel,Johan M van Rooijen,Albert J. ten Tije,Martijn P. Lolkema,Edwin Cuppen,Stefan Sleijfer,John W.M. Martens,Saskia M Wilting +14 more
TL;DR: In contrast to primary colorectal cancer (CRC) little is known about the genomic landscape of metastasized CRC as mentioned in this paper, but the authors of this paper present whole genome sequencing data of metastases of 429 CRC patients participating in the pan-cancer CPCT-02 study (NCT01855477).